Bluejay Diagnostics is a late-stage company focused on improving patient outcomes through a near patient product for triage, diagnosis and monitoring of disease progression. Co.'s diagnostic system, which Co. refers to as Symphony, which is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated into the cartridge. Symphony utilizes a sample-to-result format, which means that once a specimen is taken from the patient, it is placed in the cartridge and then the cartridge is placed inside the analyzer where the test is run without further technician intervention or additional reagent. The BJDX average annual return since 2021 is shown above.
The Average Annual Return on the BJDX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BJDX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BJDX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|